According to the American Cancer Society, the average American man has a 1 in 726 chance of getting diagnosed with breast ...

Routine screenings, awareness, and discussion with medical professionals are essential in detecting this early stage and maximizing results.

The results of a clinical trial published last month targeted breast cancer "sleeper cells," which are cells that break away from the main tumor and can resurface later to spread cancer throughout the ...

ENHERTU Reduced Risk of Disease Recurrence or Death by 53% vs. T-DM1 in High-Risk HER2 Positive Early Breast Cancer After ...

“The long-term outcomes from CheckMate 238 confirm that nivolumab is a proven adjuvant treatment for patients with melanoma at high risk for recurrence, with sustained improvement in recurrence-free ...

A machine learning model may be a valid method of determining the risk for recurrence of MS among individuals who discontinue ...

A retrospective study found that the 313-SNP breast cancer polygenic risk score (PRS 313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ ...

Ovarian cancer in women remains one of the most difficult cancers to diagnose. This is partly because its symptoms are not ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

These cancer patients had a common gene mutation called PIK3CA. There was a 7.7 percent recurrence rate in the aspirin takers compared to a 14 percent return in the people on placebo. That is a ...